

Covalon Announces Exciting New Clinical Research Evaluating VALGuard® Vascular Access Line Guard

Study results have been selected for presentation at two prestigious scientific meetings and are advancing to publication

MISSISSAUGA, Ontario – May 27, 2025 – (BUSINESS WIRE) – Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that exciting results from a clinical study evaluating the use of its VALGuard® Vascular Access Line Guard will be presented at two notable scientific meetings in the fall and are advancing through the publication process in a well-regarded academic journal.

The study, conducted independent of Covalon, was a prospective pre- and post- intervention study of VALGuard® across critical and acute care units focused on the reduction of Central Line-Associated Blood Stream Infections (CLABSIs).

"Blood streams infections are a serious, but largely preventable complication that tragically affect hundreds of thousands of patients each year, with a mortality rate estimated at 15% to 20%," said Dr. Kate Evelyn, Vice President of Clinical Affairs for Covalon. "Major hospitals all over the United States are adding VALGuard® as an important part of their infection prevention program's toolkit to protect intravenous lines from gross contamination, a known source of infection. The study results provide impactful real-world evidence on the use of VALGuard®. The forthcoming publication of this investigator-initiated study is a testament to the dedication of the research team and our shared goal of advancing patient care."

As the authors advance the study through the final stages of the peer review process toward publication, they look forward to presenting their findings to their peers at two prestigious scientific conferences this fall – September's Association for Vascular Access Annual Scientific Meeting, the premier platform for the latest innovations and emerging technologies in vascular access, followed by October's American Nurses Credentialing Center (ANCC) Magnet Pathway Conference, which attracts more than 11,000 nursing leaders and professionals from around the world.

About VALGuard

VALGuard® is a unique innovative transparent line guard designed to protect IV line connections and hubs from external contaminants, including body fluids, and secretions that can lead to serious, life-threatening blood stream infections.

Those interested in learning about Covalon's solutions may visit www.covalon.com or follow Covalon on [LinkedIn](#), [Facebook](#), [Instagram](#), or [X](#).

To learn more about Covalon, please contact:

Investor Relations, Covalon Technologies Ltd.
Email: investors@covalon.com
Website: <https://covalon.com/>



About Covalon

Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at www.covalon.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might", "will" or "will be taken", "occur", or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.

SOURCE Covalon Technologies Ltd.